+30.4%
GSK vs TXG
+372.5%
-342.1%
-18.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | TXG | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.9% | -0.9% | -1.0% | -1.9% |
| 7D | -1.8% | +1.8% | -3.6% | -1.9% |
| 30D | -2.2% | +32.0% | -34.2% | -2.8% |
| 3M | -1.8% | +87.0% | -88.8% | -3.3% |
| 6M | -10.6% | +180.1% | -190.7% | -13.8% |
| YTD | +4.4% | +284.1% | -279.7% | +0.8% |
| 1Y | +30.4% | +361.7% | -331.3% | +27.5% |
| All | +30.4% | +372.5% | -342.1% | +27.5% |
Cumulative growth
Daily Returns
Daily percentage return beside TXG.
Daily Out/Under-Performance
Portfolio return minus TXG return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × TXG return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded TXG wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling